p53-regulated GML gene expression in non-small cell lung cancer: a promising relationship to cisplatin chemosensitivity
- 31 March 2000
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 36 (4), 489-495
- https://doi.org/10.1016/s0959-8049(99)00261-0
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugsJournal of Surgical Oncology, 1998
- Overexpression of GML Promotes Radiation-Induced Cell Cycle Arrest and ApoptosisBiochemical and Biophysical Research Communications, 1997
- GML sensitizes cancer cells to Taxol by induction of apoptosisOncogene, 1997
- Genomic Structure and Chromosomal Localization of GML (GPI-Anchored Molecule-like Protein), a Gene Induced by p53Genomics, 1997
- Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.Thorax, 1996
- The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion.The Journal of cell biology, 1995
- Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancerLung Cancer, 1995
- Tumor suppressor p53 is a direct transcriptional activator of the human bax geneCell, 1995
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- GPI-Anchored Cell-Surface Molecules Complexed to Protein Tyrosine KinasesScience, 1991